Cell Therapeutics granted market access for Pixuvri in Italy
Pixuvri has been approved as a monotherapy to treat adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, including those with aggressive B-cell NHL who failed
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.